Marijuana-derived epilepsy drug doubles sales, sending GW Pharma stock soaring
Marijuana Industry NewsMedical Marijuana August 8, 2019 MJ Shareholders 0
GW Pharmaceuticals PLC reported Tuesday afternoon that sales of its cannabis-derived epilepsy drug more than doubled from the previous quarter, sending shares spiking more than 11% higher in after-hours trading.
GW Pharmaceuticals GWPH, +10.22% reported second-quarter sales of $68.4 million for Epidiolex, which uses cannabidiol, a compound present in cannabis plants to treat certain forms of epilepsy. Wall Street analysts had forecast Epidiolex sales of $40.9 million, after GW Pharma reported sales of $33.5 million in the first quarter.
“We are pleased to report a strong second quarter of sales of Epidiolex in the U.S., reflecting high demand by U.S. patients, increased prescribing by health care providers, and ongoing progress in payer-coverage determinations,” GW Pharma Chief Executive Justin Glover said in a statement.
Since the drug’s launch, the company said more than 12,000 patients have received prescriptions for the medicine and it has been dispensed to 2,500 doctors.
Overall, the company reported second-quarter net income of $79.8 million, or 21 cents a share, compared with losses of $84 million, or 25 cents a share, in the year-ago period. The United Kingdom-based company’s net income benefited from a $104.1 million gain on the sale of one of its intangible assets. Revenue rose to $72 million from $3.3 million in the year-ago period. [Read more at MarketWatch]
MJ Shareholders
MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers
No comments so far.
Be first to leave comment below.